Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.
Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.
All hepatitis C virus genotypes respond to therapy
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.
Females, Hispanics screened less often for highly curable infection.
More patients could take advantage of shorter direct-acting antiviral treatment duration.
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
More effort needed to integrate screening with follow-up care to prevent spread of the virus.